Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | -3.33% | -0.57% | +70.59% |
Valuation
Fiscal Period: Giugno | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 18.42 | 53.38 | 21.72 | 13.42 | 20.56 | - | - |
Enterprise Value (EV) 1 | 18.42 | 53.38 | 21.72 | 13.42 | 20.56 | 20.56 | 20.56 |
P/E ratio | -2 x | -5.73 x | -2.69 x | -1.55 x | -2.38 x | -1.57 x | -3.05 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 6.85 x |
EV / Revenue | - | - | - | - | - | - | 6.85 x |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | -3.67 x | -2.36 x | -4.03 x |
FCF Yield | - | - | - | - | -27.2% | -42.3% | -24.8% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 3,837 | 11,505 | 11,554 | 11,666 | 11,814 | - | - |
Reference price 2 | 4.800 | 4.640 | 1.880 | 1.150 | 1.740 | 1.740 | 1.740 |
Announcement Date | 8/23/19 | 10/12/21 | 10/13/22 | 10/13/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: Giugno | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 3 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -8.66 | - | - | -8.943 | -7 | -11.42 | -8.8 |
Operating Margin | - | - | - | - | - | - | -293.33% |
Earnings before Tax (EBT) 1 | -8.424 | - | - | -8.589 | -8.7 | -14.8 | -8.4 |
Net income 1 | -8.424 | -8.822 | - | -8.589 | -8.7 | -14.8 | -8.4 |
Net margin | - | - | - | - | - | - | -280% |
EPS 2 | -2.400 | -0.8100 | -0.7000 | -0.7400 | -0.7300 | -1.110 | -0.5700 |
Free Cash Flow 1 | - | - | - | - | -5.6 | -8.7 | -5.1 |
FCF margin | - | - | - | - | - | - | -170% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 8/23/19 | 10/12/21 | 10/13/22 | 10/13/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
EBIT 1 | -1.788 | -1.793 | -1.622 | - | - | - | -2.185 | -1.908 | -2.4 |
Operating Margin | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.793 | -1.78 | -1.571 | - | - | - | -2.115 | -1.854 | -2.3 |
Net income 1 | -1.793 | -1.78 | -1.571 | - | - | -1.969 | -2.115 | -1.854 | -2.3 |
Net margin | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1600 | -0.1500 | -0.1400 | -0.1500 | -0.1500 | -0.1700 | -0.1800 | -0.1600 | -0.2000 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 5/16/22 | 10/13/22 | 11/14/22 | 2/14/23 | 5/15/23 | 11/14/23 | 2/14/24 | 5/15/24 | - |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2021 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -5.6 | -8.7 | -5.1 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 8/23/19 | 10/12/21 | 10/13/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.59% | 20.56M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- NNVC Stock
- Financials NanoViricides, Inc.